The Effect of Rosuvastatin and Olmesartan on the Progression of Coronary Atherosclerotic Disease
A phase 2 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 504 participants.
Also called NCT02516826
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 504 participants
- Sponsor
- Registry
-
NCT02516826
-
- Start date
- (registry gives no type)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- South Korea
- Registry status
- Unknown status
Technical summary
Registry record NCT02516826. Randomized; quadruple masking; primary purpose treatment. Start 2015-08 (registry gives no type); primary completion 2018-08 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- The Effect of Rosuvastatin and Olmesartan on the Progression of Coronary Atherosclerotic Disease
- Condition
- Coronary Syndrome
- Intervention (Drug)
- Rosuvastatin
- Intervention (Drug)
- Olmesartan
- Intervention (Drug)
- Combination
- Intervention (Drug)
- Placebo of Rosuvastatin
- Intervention (Drug)
- Placebo of Olmesartan
- Intervention (Drug)
- Placebo of Rosuvastatin/Olmesartan(Combination)
- Lead sponsor
- Samsung Medical Center
Record details
- Record id
cardio:ct-nct02516826- Content hash
f2c5d4f463188cb773f9798ef2f3eaf8d824b6dba6d365bbf9575893dba49bc1